Providing innovation and excellence for precision medicine
Lucas Antonio Diez Martínez, CEO and founder
Founded in 2012, Avamed Synergy is the first Spanish company with the vision to revolutionise cancer monitoring and personalised treatment through clinical imaging, focusing on promoting excellence in diagnostic and surgical efficiency with the highest precision. Avamed Synergy was born with the vision of transforming personalised medicine by generating new knowledge and transferring it to the health sector through the development of new technologies. With exponential growth since its foundation, it has now established itself as a clear reference in the field of medical innovation, particularly for predictive oncology.
Betting on a business model of alliances and adding experience in the sector, Avamed Synergy maintains collaboration agreements for project development with the main reference hospitals in the Spain, as well as with various associated biomedical research institutes. Their workflow is characterised by a constant commitment to scientific transfer and technological innovation in the health sector.
Avamed Synergy, promoter and participant in multiple clinical projects throughout its history, stands out in the collaboration of planning highly complex surgeries for specialties such as traumatology, neurosurgery, maxillofacial surgery, or high-precision oncological surgery. The application of their services has provided valuable information for surgeons and their teams, both at the diagnostic, surgical, and postoperative levels.
Fluxus is Avamed Synergy's most outstanding project, currently in its development phases. A unique and innovative clinical environment, assisted by artificial intelligence and deep learning in its code through advanced exclusive algorithms to provide a tumour-host interface model with multiscale data and uncertainty quantification. This will result in a significant leap in understanding tumour multi-structure, its growth dynamics, and thus contribute to clinical empowerment for a more effective treatment and the necessary surgical approach.
Fluxus has proven to be a great example of the present and future possibilities of applying new technologies in the medical field. Despite still being in its development process, it has already demonstrated its effectiveness and precision in various clinical specialties, achieving a significant reduction in false negatives when analysing tumour masses in the body. The existing prognosis for Fluxus is that it will be able to apply predictive models successfully and with maximum guarantee.
These milestones have allowed the company to attract investor interest and reap great successes throughout 2024. Avamed Synergy shows great expectations for the future. The company's intention is to continue developing advanced technologies to improve the detection, analysis, diagnosis, and treatment of complex diseases. All this, with the aim of providing medical teams with tools that improve their work, but also to provide patients with better care and quality of life during their treatments. In this way, their goal is to become a leading company in the technological and digital transformation of medicine, making a significant difference in patients' lives and empowering medical teams.
